Sivia Capital Partners LLC Makes New $351,000 Investment in Takeda Pharmaceutical Co. $TAK

Key Points

• Sivia Capital Partners LLC acquired 22,734 shares of Takeda Pharmaceutical Co. valued at approximately $351,000 during the second quarter.
• Several institutional investors have increased their stakes in Takeda Pharmaceutical, with notable increases from Intelligence Driven Advisers LLC (7.2%) and Ieq Capital LLC (4.6%).
• Takeda Pharmaceutical reported earnings of $0.52 per share for the last quarter, exceeding analyst expectations, but its revenue fell short of estimates at $7.45 billion.

Sivia Capital Partners LLC purchased a new stake in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 22,734 shares of the company's stock, valued at approximately $351,000.

Several other large investors have also recently added to or reduced their stakes in TAK. Goldman Sachs Group Inc. increased its position in Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company's stock worth $79,120,000 after buying an additional 692,404 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of Takeda Pharmaceutical during the 1st quarter valued at $51,049,000. Federated Hermes Inc. lifted its holdings in shares of Takeda Pharmaceutical by 24.6% during the 1st quarter. Federated Hermes Inc. now owns 541,919 shares of the company's stock valued at $8,058,000 after acquiring an additional 106,885 shares in the last quarter. Toronto Dominion Bank acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at $6,760,000. Finally, Royal Bank of Canada lifted its holdings in shares of Takeda Pharmaceutical by 11.0% during the 1st quarter. Royal Bank of Canada now owns 441,054 shares of the company's stock valued at $6,558,000 after acquiring an additional 43,706 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Performance

TAK stock traded up $0.05 during mid-day trading on Friday, reaching $15.07. 1,823,707 shares of the stock traded hands, compared to its average volume of 2,993,138. Takeda Pharmaceutical Co. has a 52 week low of $12.80 and a 52 week high of $15.69. The firm has a market capitalization of $47.95 billion, a PE ratio of 50.23 and a beta of 0.22. The business has a 50-day moving average of $14.82 and a two-hundred day moving average of $14.84. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The company had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, equities analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Zacks Research downgraded shares of Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a research report on Thursday, August 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Takeda Pharmaceutical presently has a consensus rating of "Hold".

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.